MNDY › analyze
MNDY · Analyze
Full analysis · 2026-08-10 · $88.62 · Technology / Software–Application · Israel (FPI)
One line: A 252,000-customer work-management platform whose entire recent growth premium came from a single 2024 price increase that laps this quarter — management has said on the record that nothing organic replaces it, and the guide shows growth cliffing 22% → 16%. But the balance sheet is a fortress, owner earnings are genuinely positive, and contracted revenue is growing ahead of the guide. WATCH, conviction 5.5 — a good business at a fair price with one dated, resolvable unknown.
⚠️ Q2 FY2026 was reported this morning (2026-08-10, pre-open). Stock −4.8% on the day from $93.13. This analysis incorporates it.
0. Knowledge-base check (Step 0)
kb.py find MNDY returned two live notes, and one of them turns out to be wrong about this name —
see §1. Knowledge/Themes/software-saas.md lists MNDY in its ticker roster but the name was never
individually analyzed. The governing diagnostic from that note — can the company still take price? —
was 2-for-2 (ADBE ✗, TEAM ✓). MNDY makes it 3-for-3, and it fails.
1. 🔴 KB CORRECTION — the share-count pitfall is a FALSE POSITIVE on this name
[[pitfall-yahoo-share-count-dual-class-fpi]] lists MNDY as its 5th confirmed case at "~−25.6% understatement," reasoning that Yahoo's 42.27M contradicted FY2025 diluted weighted-average of 53.09M.
That entry is wrong and must be retracted.
- monday.com is single-class. One vote per ordinary share (FY2025 20-F, Note 13). There is one non-economic "founder share" held by a Co-CEO carrying veto rights — a governance instrument, not a share class. The pitfall's precondition (dual class) is absent.
- Yahoo's 42,274,119 is correct and current, matching the Q2 FY26 6-K cover exactly.
| As of | Ordinary shares outstanding |
|---|---|
| 2024-12-31 | 50,773,337 |
| 2025-12-31 | 51,160,822 |
| 2026-06-30 | 42,274,119 |
The gap is a buyback, not a vendor failure: 51,160,822 − 9,602,294 repurchased + 715,591 issued =
42,274,119. The company retired 10,486,207 shares for $870.0M — 18.8% of itself in six months.
The note's own rule — "always take the third reading, diluted weighted-average, and treat a gap as the real signal" — is what produced the false positive. A diluted weighted-average is a period figure; comparing it to a point-in-time count flags every aggressive repurchaser as a vendor error. The detection method needs a fourth step: reconcile the gap against the financing section's buyback line before calling it a vendor failure. NU / TEAM / WDAY / ASAN remain valid — the note is 4-for-5, not 5-for-5. The claim has also propagated into
Watchlist.mdline 125 (TEAM), which repeats "MNDY ~−26%" and needs the same fix.
Corrected figures used throughout this report:
| Value | |
|---|---|
| Shares outstanding (2026-06-30) | 42,274,119 |
| Fully diluted (+1,150,320 options @ WA $68.12, +2,604,847 RSU/PSU) | 46,029,286 |
| Market cap (basic / fully diluted) | $3.75B / $4.08B |
| Cash $853.4M + securities $219.4M | $1,072.8M |
| EV (fully diluted, ex-leases) | ~$3.01B |
fin.py's reported EV of $3.44B is ~$430M too high on the fully diluted basis and $767M too high on
the basic basis. (Lease liabilities of ~$177M are excluded from EV above; MNDY has no financial debt —
the entire "Total Debt" line is capital leases.)
2. 🚩 The reported earnings are an artifact — the tripwire fired here too
FY2025 net margin 9.6% sat above operating margin −0.14%. Under [[pattern-net-margin-above-operating-margin-is-a-tripwire]], the source must be named. It reconciles to the dollar:
| ($000) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income (loss) | (38,585) | (21,034) | (1,748) |
| Financial income, net (≈ interest) | 41,911 | 55,500 | 61,065 |
| Pretax income | 3,326 | 34,466 | 59,317 |
| Income tax benefit (expense) | (5,203) | (2,094) | +59,425 |
| Net income | (1,877) | 32,372 | 118,742 |
| Effective tax rate | 156.0% | 6.0% | (100.2)% |
Net income 118,742 − operating loss (1,748) = 120,490
Financial income 61,065 + tax benefit 59,425 = 120,490 ✓ exact, no other items
~51% of FY2025 net income was a one-time non-cash tax entry; ~49% was interest on the cash pile. Operations contributed a $1.7M LOSS. The 20-F confirms: "reversal of the valuation allowance on the Company's deferred tax assets in the fourth quarter of 2025 of $61.1 million… a non-cash income tax benefit." Valuation allowance $(62.2)M → $0. Cash taxes actually paid in FY2025: $4.9M.
This is a fourth confirmed instance of [[pitfall-tax-valuation-allowance-round-trip-breaks-eps]] (after QCOM, DT, and PEGA in this same session), and FY2024's 6.0% effective rate is exactly the near-zero leading indicator the Dynatrace case established.
Both props are now gone: - Tax: H1 2026 flipped to a $4.05M expense, 11.4% ETR; remaining NOLs "fully utilised during 2026." Israel's Pillar Two QDMTT took effect 2026-01-01 (15% minimum on Israeli profits). - Interest: financial income Q1 $10.38M → Q2 $6.96M, −51% YoY as the buyback consumed the cash ($1,503M → $853M). Annualizing Q2 gives ~$28M vs $61M in FY25 — a ~$33M/yr self-inflicted headwind. - Q2 2026 GAAP net income was $3.46M.
Yahoo's
PE(ttm) 38.70,EPS(ttm) $2.29and the Graham IV of $28.53 are all built on contaminated earnings and should be treated as VOID, not as valuation signals.PE(fwd) 15.95is a non-GAAP construct that adds back SBC and is not comparable.
3. Fundamentals
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 (guide) | Q4 FY26 (implied) | |
|---|---|---|---|---|---|
| Revenue | $333.9M | $351.3M | $364.6M | $368–370M | ~$385.1M |
| YoY growth | +25% | +24.4% | +21.9% | +16.4% | +15.3% |
| Overall NDR | 110% | 110% | 109% | ~108% | ~108% |
| NDR >$100k ARR | 115% | 115% | 115% | ||
| >$50k ARR customers | — | 4,547 (+32%) | 4,834 (+31%) | ||
| >$500k ARR customers | — | 99 (+74%) | 114 (+68%) | ||
| GAAP operating income | +$2.4M | +$19.8M | −$1.5M (incl. $21.4M restructuring) | ||
| Non-GAAP operating income | $41.9M (13%) | $49.0M (14%) | $61.1M (17%) | $57–59M | |
| Adjusted FCF | $56.7M | $102.8M | $52.3M (14%) (PY: $64.1M, 21%) |
Health scorecard
| Metric | Value | Read |
|---|---|---|
| Revenue TTM | $1,366.6M | ✅ but decelerating to +16% guided |
| Revenue 3yr CAGR | 33.4% | historical, not forward |
| GAAP operating income TTM | ~+$8M | ⚠️ first positive year ever, immediately back to −$1.5M in Q2 |
| Gross margin | 89.6% → 88.3% | ⚠️ falling; guided to mid-80s on AI compute cost |
| FY26E adjusted FCF | $280–290M vs FY25 $322.7M | 🔴 DOWN 10–13% in dollars on +19–20% revenue |
| SBC TTM | $159.9M (11.7% of rev) | 🚩 dollars fall only because the stock fell — see below |
| SBC / FCF | 53.7% (3 straight years >48%) | 🔴 the March-cohort disqualifier |
| SBC-adj FCF FY26E | ~$135M (9% margin) | 🔴 thin |
| Net cash | +$1,073M | ✅ genuine, no financial debt |
| Revenue per employee | $393.6K → $387.6K → $390.5K | 🚩 flat for three years — no AI productivity gain |
🚩 The SBC improvement is a share-price artifact, not cost discipline
I initially read MNDY's falling SBC dollars as genuine (unlike TEAM's cash-comp swap), because operating income improved at the same time. That was wrong. The filings show the opposite:
| H1 2025 | H1 2026 | |
|---|---|---|
| RSUs/PSUs outstanding | 1,396,897 (Dec-25) | 2,604,847 (Jun-26) — +86% in six months |
| RSUs/PSUs granted in the half | — | 1,783,617 (more than the entire opening balance) |
| WA grant-date fair value, options | $252.64 | $73.57 (−71%) |
| Unamortized SBC | $241.3M | $204.0M — but UP $33.7M from Dec-31-2025's $170.3M |
They granted 86% more units at roughly one-third the price per unit. Reported SBC fell ~19% purely because the stock fell ~70%. Shareholders are being diluted faster while the P&L charge looks smaller, and future SBC expense is being rebuilt, not wound down.
And total compensation is rising, not falling. No total payroll is disclosed, but Israel's statutory Section 14 severance deposit (a fixed 8.33% of salary) provides a handle:
| FY2023 | FY2024 | FY2025 | |
|---|---|---|---|
| Israeli severance expense (confirmed) | $8,435K | $11,086K | $15,636K |
| Implied Israeli cash salary base (inferred, ÷8.33%) | ~$101.3M | ~$133.1M | ~$187.7M (+41%) |
| Israeli headcount | n/d | 1,494 | 1,729 (+15.7%) |
Israeli cash payroll grew ~41% on 15.7% headcount growth — roughly +22% per head — while SBC per employee was flat-to-down. This is the same equity-for-cash pattern as [[pattern-equity-for-cash-comp-swap-is-owner-earnings-neutral]], and it means the two-question SBC test from the TEAM work returns: (1) is SBC falling? yes — for the wrong reason. (2) is total comp falling? no.
⚠️ H2 2026 SBC optics will be contaminated twice — by the share-price effect and by ~$15M of non-cash SBC credits (forfeiture reversals) inside the July restructuring charge.
4. 🎯 The pricing-power test — MNDY FAILS, and management said so on the record
This is the heart of the analysis and it makes the framework 3-for-3.
The one price increase, and its expiry
| Date | Action | Magnitude |
|---|---|---|
| 2024-01/02 | Broad increase across all products and plans. Basic $8→$9, Standard $10→$12, Pro $16→$19 | +11% to +21% |
| through H1 2025 | second wave — 20-F: "pricing adjustments implemented during 2024 and the first half of 2025 across our entire customer base" | |
| 2026-02-10 | monday service ONLY, +18% | one product, not the core |
| 2026 | NO new broad work-management increase. List is essentially the January-2024 schedule. | — |
🔴 CFO Eliran Glazer, Q1 FY26 call, 2026-05-11 (primary LSEG transcript)
"As a reminder, we are lapping the pricing actions from 2024… And they increased our NDR by 12%. We're going to lap this at the end of Q2. And we don't believe that expansion or new adoption will now be enough to offset some of the pricing growth that we have seen in the past."
Management states that (a) ~12 points of NDR came from a price increase, (b) it rolls off at the end of Q2 2026, and (c) organic expansion cannot replace it. That single quote explains the entire 24% → 22% → 16% growth cliff, which lands in the exact quarter the lap completes. The 20-F corroborates: Q4 2025 NDR "reflects continued seat and product expansion… partially offset by the anniversary of pricing adjustments."
(Caveat: machine transcript; "12%" is ambiguous between 12 points of NDR and a 12% price action. If read as 12 points, underlying expansion NDR is ~98% — negative organic net expansion. Both readings support the same conclusion. Verifying against the audio is the highest-value follow-up available.)
The seat/AI question — denied for today, conceded for tomorrow
Casey George (CRO), Q1, answering directly: "We have not seen any degradation in demand relative to seats.… Seat demand continues to be very solid."
Eran Zinman (Co-CEO), same call, prepared remarks: "As AI agent takes on more work across organizations, revenue expands naturally without requiring additional seats purchases."
Zinman, Q2: "Before the changes in the product and pricing, the only way customers could expand was to add more people and more seats."
They built a consumption layer precisely because they do not expect seats to carry growth. And the company demonstrated the bear thesis on its own P&L: it cut 20% of its workforce (~630 roles) on 2026-07-22, with Glazer citing "the productivity gains AI is already delivering across our organization." A company priced per knowledge worker proving on itself that AI needs fewer of them is the same contradiction flagged in the TEAM analysis.
The replacement revenue is small, opt-in, and lower-margin
Seats-plus-credits launched 2026-05-06, new customers only; existing customers opt-in over "a couple of years" with a credit calculator that converts existing add-on spend cost-neutrally. monday sidekick is currently free. Enterprise customers receive "complementary AI packages."
AI ARR has never been disclosed in dollars — only "doubled from Q1, representing 17% of net new ARR in Q2." Inferring from the $13.3M sequential revenue add (~$53M annualized net new ARR), 17% ≈ ~$9M added in Q2, implying cumulative AI ARR of ~$15–20M ≈ 1% of revenue. Glazer, Q1: "It's still early stage… we didn't assume any significant impact or any impact on the numbers."
And credits carry COGS. Glazer: "we expect gross margin to be mid-80s. We were used to 90%, but because of the computing cost of AI." Already visible — Q2 cost of revenue +37% on +22% revenue. The replacement revenue is structurally lower-margin than the seat revenue it replaces.
🚩 Seat count is not disclosed
The FY2025 20-F uses the word "seat" twice and discloses no seat count, no seat growth rate, and no split between volume and price/mix. For a per-seat business that is a material disclosure gap. Given 12 points of NDR came from price and total NDR is 109%, you cannot rule out that unit seat growth in the SMB base is near zero or negative. The company has chosen not to let you check.
5. Moat
Rating: 5.5/10. A real switching-cost and data-gravity moat at the top of the customer base, wrapped around a very large, very replaceable tail.
The concentration, quantified (Q2 FY26 slides): 252,000 customers. $50k+ ARR = 43% of ARR (up from 38%); $100k+ = 30%; $500k+ = 7%.
57% of ARR comes from customers below $50k ARR, and 98.1% of customers (247,000 of 252,000) sit in that tail. Blended revenue per customer ≈ $5,800/year.
The enterprise shift is genuinely working — $500k+ customers +68% to 114, their ARR share 5% → 7%; $50k+ share 38% → 43%; 34% of the $50k+ cohort now multi-product (from 29%); monday CRM crossed $100M ARR. But it is working from a small base against a very large tail — and the tail is exactly the cohort Google AI Overviews damaged in August 2025 (co-CEOs at the time: "the drop is mostly in general interest"), which has never recovered. The Q3 guide explicitly assumes no rebound in performance marketing.
Honest counter-evidence, weighted: - Gross retention is at all-time highs. Glazer: "It's not related to churn. Actually, our growth retention is at all-time high." The NDR decline is the price lap, not customers leaving. - RPO $937M +34% and cRPO $750M +27%, both faster than the 22% revenue growth. Customers are signing longer and larger — the same signal that made Atlassian defensible, and the hardest bear datapoint to explain away.
Adversarial test. Microsoft is the live threat — Planner/Loop/Copilot bundled into an M365 licence the customer already pays for attacks precisely the 57% of ARR that is price-sensitive and low-commitment. Atlassian attacks from above with a converging suite and accelerating growth. LLM-native prompt-to-app tools (Lovable, Bolt, v0, Replit Agent) attack the new-logo funnel that is already impaired.
Does GenAI commoditize "no-code work OS"? It commoditizes the creation of an app; it does not commoditize the governance and data gravity of one already running the company's work — 252,000 tenants' permissions, integrations and audit trails. But note the same correction made on Atlassian: this is a switching-cost/data-gravity moat, NOT a network effect. Calling it a network effect inflates the multiple. And it is much weaker in the sub-$50k tail, where a monday board genuinely is replaceable.
The moat holds only if the enterprise mix shift outruns the SMB erosion. The $500k+ cohort going 5% → 7% of ARR per year is the exact race to watch. Evergreen: no.
6. Valuation
DYT/DDM N/A (no dividend). Graham IV is VOID — it is computed on contaminated EPS (§2); the vendor's $28.53 should not be quoted.
| Frame | Multiple |
|---|---|
| EV / TTM revenue | 2.20x |
| EV / FY26E revenue ($1,470M) | 2.05x |
| EV / FY26E adjusted FCF ($285M) | 10.5x |
| EV / SBC-adjusted FCF (~$135M) | ~22.3x |
| Normalized GAAP P/E | ~83x (meaningless — operations earn ~nothing) |
(EV = 46.03M fully diluted × $88.62 − $1,072.8M net cash = $3.01B.)
Peer check: MNDY at ~2.0x FY26E revenue on 19–20% growth vs Asana at 2.42x on 10% growth — MNDY is cheaper and growing twice as fast. Against Atlassian at ~$38.6B EV growing 28% with Cloud accelerating, MNDY is decelerating. This is not a category problem; it is a mix problem.
DCF, on SBC-adjusted FCF, 10% discount, FY28 base:
| Scenario | Assumptions | Value/share |
|---|---|---|
| Bear | growth decays to 10%, SBC-adj FCF margin stays ~9% | $66 |
| Base | growth ~15–16% post-lap, margin reaches 13% by FY28 | $92 |
| Bull | growth 18%, AI credits scale, margin 16% | $124 |
Fair value: $66–$124, central ~$92. At $88.62 the stock is roughly fair, with a modest discount to the central case — the −60% drawdown has removed the bubble rather than created a bargain, but it has not overshot either. [[principle-down-a-lot-is-not-cheap]] applies to the size of the drawdown, not to the fundamentals underneath it.
⚖️ The base case leans on cRPO, and that deserves to be explicit
The guide says +16% for Q3. cRPO — contracted revenue due in the next twelve months — grew +27%, and total RPO +34%, both well ahead of the 22% revenue print. Those are the forward-looking figures, and they point up while the guide points down. The CFO's framing supports reading the guide as conservative:
"We prefer to underpromise and overdeliver through a transition" … "we did not want to layer an aggressive top-line rate on top of execution risk" … and the guide "does not assume a rebound in performance marketing."
A guide that assumes no marketing recovery, set against cRPO growing 27%, is a floor rather than a forecast. The base case therefore assumes post-lap organic growth of 15–16%, not the guided 16% decelerating further. This is the single assumption the whole valuation turns on, and Q3 tests it directly.
🚩 The hidden guide-down, and the FCF decline
There was no headline FY26 revenue cut in 2026 — but the arithmetic shows one: - At the Q1 print, implied H2 = $1,470.5M − $351.3M − $355M = $764.2M - At the Q2 print, implied H2 = $1,470.0M − $715.9M = $754.1M - Implied H2 was cut $10.1M — slightly more than the entire $9.6M Q2 beat. The beat was absorbed, not flowed through. Classic beat-and-lower-the-rest.
And FY26 adjusted FCF is guided DOWN in absolute dollars — $322.7M → $280–290M, −10% to −13% on +19–20% revenue growth. H1 actual $155.1M vs $173.6M, margin 30% → 22%. FCF has fallen YoY three quarters running. (Partly self-inflicted: the CFO attributes ~$20M to forgone interest from the accelerated buyback.)
The entire non-GAAP margin expansion — 13% → 16% — is the layoff, on unchanged revenue.
7. Sentiment & positioning
🚩 The buyback backstop is exhausted. The $870M authorization is 100% utilized — the Q2 release states "no shares are available for future share repurchases under the program." $553M of it was spent in Q1 2026 buying directly into the February crash at ~$76 — genuinely high-conviction, and it worked (H1 tranche ~16% in the money). But: 1. The largest marginal buyer of MNDY stock in 2026 has left the market, with no successor announced in any filing through 2026-08-10. 2. The dilution offset is gone while RSUs outstanding just grew 86%. Share count should now start rising again. 3. It was funded by the interest-bearing cash — converting a ~$33M/yr recurring income stream (which was the entire pretax profit) into a one-time share retirement.
(Governance positive: on 2026-07-01 the Board cancelled 10,875,000 unissued reserved shares, killing the evergreen top-up. Plan dilution now 9.94% fully diluted.)
Analysts: the price targets reset, the ratings never did. Feb 9–10 2026 saw ten PT cuts of 30–50% (Needham $250→$125, Guggenheim $250→$180, KeyBanc $220→$140, Wells Fargo $200→$130, BofA $157→$95) — nine of eleven kept Buy/Overweight. Jefferies cut $260→$80 on Feb 23. Today: Cantor and Capital One both downgraded to Hold. Consensus is 13 Strong Buy / 5 Buy / 7 Hold and ZERO SELL across 25 analysts, mean PT $110.04 — on a stock down 60% after two guidance disappointments, a 20% RIF and a securities class action. That is unfinished business.
🔍 Insider record — the most striking item, and it cuts both ways. As an FPI, MNDY insiders are exempt from Section 16: the entire lifetime Form 4 record is three filings, all from the US-based CRO. There are no founder Forms 4 and no 10b5-1 disclosure at all. The real record is Form 144: 100 filings from 2023-12-15 through 2025-12-09 — near-weekly affiliate selling for two years — then ZERO in 2026. Frequent filers include Co-CEO Eran Zinman and director Aviad Eyal; the last proposed 60,000 shares at ~$162.
Selling ran continuously for two years, stopped dead on 2025-12-09 — nine weeks before the disclosure that halved the stock — and has not resumed through the entire 60% drawdown. Both readings are legitimate: benign (counsel closed the window; not selling into a crash is normal) and uncomfortable (the timing, and that one of the last disclosed sale dates, 2025-09-17, is the first day of the securities class period). Because MNDY is an FPI there is no 10b5-1 disclosure to tell you which.
Institutions: rotation from conviction to arbitrage. 82.9% of shares out. Q1'26 top adds are Renaissance +93%, Two Sigma +441%, D.E. Shaw +318%, Goldman +257%; 137 added vs 252 reduced. WCM Investment Management (7.4%, a fundamental long-only holder) appears to have exited entirely. Quant and multi-strat desks replacing long-only holders makes the stock more reflexive, not less.
Short interest ~19.7% of the true ~35M float (6,898,980 shares, 7.8 days to cover). Published figures of 17.36% use the stale 51.16M count. Squeeze mechanics are real — but the buyback that was mechanically tightening the float has stopped.
⚖️ Securities litigation: Potter v. monday.com Ltd., 26-cv-01956 (S.D.N.Y.), class period 2025-09-17 → 2026-02-06. Alleges the $1.8B FY2027 "base case" presented at the Sept 17 2025 Investor Day was misleading when made, and was reiterated on the Nov 10 call; corrective disclosure 2026-02-09 drove −21%. Lead-plaintiff deadline passed 2026-05-11; docket status beyond that unknown.
Israel exposure: 1,729 of 3,155 employees (54.8%), R&D heavily concentrated. No operational disruption disclosed in any period. The material exposure is currency and tax, not war — shekel appreciation cost ~190bps of Q1 operating margin, and Pillar Two QDMTT began 2026-01-01.
8. Synthesis — weighted verdict
Tensions, resolved:
| Tension | Resolution |
|---|---|
| "2.0x revenue on 20% growth is cheap" vs "growth is cliffing to 16%" | The multiple is cheap against the trailing growth rate, which management has told you is ending. Price the forward 15–16%, not the trailing 22%. At 15% growth, 2.0x revenue and 22x owner earnings is fair, not cheap. |
| Bull: "RPO +34%, gross retention at all-time highs" vs Bear: "NDR 110→109, growth cliff" | Both true, and they describe different cohorts. The enterprise book is genuinely strengthening (RPO, $500k+ customers +68%). The SMB tail — 57% of ARR — is stalled. The company average is the blend, and the blend is decelerating. |
| "GAAP operating profitability finally achieved" vs "Q2 op income back to −$1.5M" | Q2 included $21.4M of restructuring. Underlying is ~+$20M, ~5% margin. Real but thin, and it took five years. |
| Fundamentals: "SBC falling" vs filings: "RSUs +86%" | The filings win. The SBC decline is a share-price artifact; unamortized SBC rose $33.7M. |
Verdict: WATCH — conviction 5.5 / 10
⚠️ Scored 4.5 on first pass; corrected to 5.5 the same day. The 4.5 was a band error, not a judgement call. [[principle-conviction-scale-range-not-resolution]] defines 3.0–4.5 as "Avoid / value trap / thesis impaired" and 5.0–6.0 as "Hold-only, or interesting with a named flaw. Not an add." This report's own conclusion — the business is not broken, the price is not low enough — is the literal definition of the second band. Three cross-checks confirm the original score was wrong: (1) PEGA scored 5.5 while contracting (ACV sequentially negative) against MNDY growing 22%; (2) TEAM carries 6.5 with SBC-adj FCF of −$288M and net cash down 87%, against MNDY's +$135M and $1.07B intact; (3) I under-weighted cRPO +27% against a +16% guide — a forward indicator pointing the opposite way to the guidance. The verdict (WATCH, no position) is unchanged; the rank was miscalibrated. Fair value moves $86 → $92 central on the cRPO re-weighting.
The bull case. A 252,000-customer platform with $1.07B net cash and no debt, at ~2.0x forward revenue and 10.5x headline FCF, where RPO is growing 34% (faster than revenue), gross retention is at an all-time high, the $500k+ enterprise cohort is up 68%, management retired 19% of the company into its own crash at ~$76, and a consumption-priced AI layer is live and doubling. If the pricing lap is a one-quarter optical event and organic growth settles at 15%+, this is worth $110–120.
The bear case. Management has stated on the record that ~12 points of NDR came from a 2024 price increase, that it laps this quarter, and that organic expansion cannot replace it — and the guide confirms it, cliffing 22% → 16%. Reported earnings are ~100% tax reversal plus interest, and both props are gone. Free cash flow is guided down 10–13% in dollars on 20% revenue growth. SBC dollars fall only because the stock fell, while RSUs outstanding grew 86%. Gross margin is heading from 90% to mid-80s because the replacement revenue carries compute cost. The buyback that was the marginal bid is 100% exhausted with no successor. 57% of ARR sits in a 247,000-customer tail that Google AI Overviews broke and that Microsoft can attack with a bundled licence. And 25 analysts still have zero sells.
Why 5.5, and not lower. The single most important variable — can this company still take price? — resolves negative, with a management quote, a date, and a quantified magnitude. That is the cleanest failure of the diagnostic in the four cases run; ADBE's had to be inferred from a guide-down, MNDY's is stated outright. Fair value sits near the current price, so you are not yet being paid much to take the deceleration risk.
But a failed pricing test is not a failed business, and the distinction is the whole score. ADBE's price deferral was open-ended — a standing statement that it could not raise prices on its flagship. MNDY's headwind is a lapping comparison: arithmetic, one-time, and self-limiting. After Q4 FY26 the base resets and reported growth becomes organic growth, whatever that turns out to be. Underneath it sit 88% gross margins, $1.07B of net cash (28% of market cap), genuinely positive SBC-adjusted owner earnings of ~$135M, gross retention at an all-time high, a $500k+ enterprise cohort up 68%, and contracted revenue growing 27–34% — faster than the business is being guided to grow.
Why not 6.5 (the shortlist gate). Three unresolved items, any one of which would keep it off a shortlist: (1) organic NDR is genuinely unknown — if the CFO's "12%" means 12 points of NDR, then underlying net expansion is ~98%, i.e. negative, and all growth must come from an impaired new-logo funnel; (2) fair value ≈ price, so there is no margin of safety; (3) the buyback that was the marginal bid is exhausted with no successor. Item (1) is the crux, and it resolves in one print.
Key risks: (1) Q3 is the first post-lap quarter and the guide already assumes no marketing rebound — a miss there re-rates hard; (2) no buyback support beneath the stock; (3) AI credits carry COGS and dilute gross margin as they scale; (4) SMB tail exposure to Microsoft bundling; (5) FPI status means you will never see a founder Form 4.
A portfolio-specific passage was removed from the public build.
🚫 Disposition — NOT TRACKED (user decision, 2026-08-10)
No position, and not added to Watchlist.md.
The reason is portfolio overlap, not the score. MNDY is a direct competitor of TEAM, held at $138.44 and re-underwritten 2026-08-07 at conviction 6.5 — and the KB's own comparison has TEAM accelerating (Cloud 26→26→29→31%) while MNDY decelerates (24→22→16%). Adding the weaker of two direct competitors, into a book already carrying 20+ enterprise-software names, is the wrong side of that trade at any conviction level. This argument is equally strong at 5.5 as it was at 4.5, which is why the score was not used to justify the decision.
Scoring note. First pass recorded 4.5. That was a band error: [[principle-conviction-scale-range-not-resolution]] defines 3.0–4.5 as "Avoid / value trap / thesis impaired", and this report's own conclusion — the business is not broken, the price is not low enough — is the definition of the 5.0–6.0 band. Corrected to 5.5 and left there, because writing down AVOID to rationalise a not-tracked decision would put a conclusion in the archive that the evidence does not support. The disposition is a capital-attention choice; the score is a finding. They are allowed to diverge, and here they do.
If the overlap ever resolves — TEAM sold, or the software concentration reduced — the re-entry conditions are below.
Does it grow into a worthy target? — the path, if ever revisited
Yes, and the path is short and dated. This is a business where the bear case is a comparison artifact with a known expiry, not a structural break. What has to be true:
| # | Condition | When it resolves |
|---|---|---|
| 1 | Post-lap organic growth lands ≥15% — the guide is 16% with no marketing rebound assumed, and cRPO says +27% | Q3 print, ~2026-11-09 |
| 2 | Organic NDR holds ≥110% once the pricing anniversary is out of the base | Q3–Q4 FY26 |
| 3 | AI credits disclosed in dollars and scaling past ~3% of revenue — proves the seat-decoupling works | FY27 guidance, Feb 2027 |
| 4 | A new buyback authorization restores the marginal bid and offsets the +86% RSU growth | any time |
| 5 | Price in the $65–75 zone alongside any of the above | market-dependent |
Conditions 1 and 2 alone would take this to 6.5–7.0 — a 15%-growing, 88%-gross-margin platform with a quarter of its market cap in cash and positive owner earnings is worth materially more than 2.0x revenue. Condition 1 failing (growth below 13%) takes it to 4.0 and it becomes the value trap the first pass mistakenly scored it as. The asymmetry is genuine and it resolves in roughly ninety days, which is an unusually clean setup for a watchlist name — the reason to wait here is a date, not a doubt.
9. What would change this verdict
🟢 Upgrade to 6.0+: Q3 revenue growth lands above 18% (i.e. the lap was less damaging than guided) · a new buyback authorization is announced · AI credit ARR is disclosed in dollars and exceeds 3% of revenue · a broad core-product price increase is taken · NDR stabilizes ≥110% post-lap · SBC/revenue below 10% with unamortized SBC falling.
🔴 Downgrade / avoid: Q3 growth below 15% · NDR below 106% · FY27 guided below 14% · gross margin below 85% · share count rising yoy with no buyback · adverse ruling in Potter · $50k+ ARR share stops climbing.
Next catalyst: Q3 FY26 print, ~2026-11-09. This is the quarter — the first without the 2024 pricing tailwind. Watch organic NDR and the $50k+/$500k+ cohort counts; revenue will be the least informative line because the lap is already guided.